From Nasdaq: 2025-06-16 01:27:00

Genentech, part of Roche Group, will move prasinezumab into Phase III clinical trials for early Parkinson’s disease based on positive results from Phase IIb PADOVA study and ongoing open-label extensions. The PASADENA and PADOVA OLE studies are assessing the long-term safety and efficacy of prasinezumab in over 750 early-stage Parkinson’s patients. In 2013, Genentech and Prothena signed a deal to develop and commercialize monoclonal antibodies like prasinezumab targeting aggregated alpha-synuclein for Parkinson’s treatment. This decision marks a significant step forward in potential treatment options for Parkinson’s disease.



Read more at Nasdaq: Genentech Advances Prasinezumab To Phase III Trials In Early Parkinson’s Disease